Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Clinically-relevant in vitro and in vivo Oncology Models for Drug Discovery

The success rate in predicting clinical efficacy of anti-cancer modalities using current xenograft models has been reported to be only 30-40%. Standard xenograft models use cell lines that are maintained in plastic and have adapted to grow independently of the tumour microenvironment, resulting in models with genetic and phenotypic characteristics distinct from that seen in the clinic. Rajendra Kumari and Martin Page at PRECOS look at why, in the attempt to reduce drug attrition and improve clinical predictivity, patient-derived xenograft tumours are being used to improve and refine preclinical modelling.

https://international-pharma.com/wp-content/uploads/2012/09/Pages-from-IPI-Volume4Issue3-53.pdf
Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025